Takeda Pharmaceutical Co Ltd ADR Price, Chart & Factor Analysis
Free Data & Analytics AccessLatest earnings: October 29, 2026 results vs estimates
Takeda Pharmaceutical Co Ltd ADR Forecast
Takeda Pharmaceutical Co Ltd ADR short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 19.4% a year, a typical one-standard-deviation range is 19.46–20.56 over a week, 18.89–21.13 over a month and 16.13–23.89 over a year. (Signals as of 1 Nov 2026.)
Takeda Pharmaceutical Co Ltd ADR Price Chart
Takeda Pharmaceutical Co Ltd ADR Factors
Research on Takeda Pharmaceutical Co Ltd ADR
Explore MacroFinance macro & markets research and analysis.
Takeda Pharmaceutical Co Ltd ADR Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Takeda Pharmaceutical Co Ltd ADR; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Takeda Pharmaceutical Co Ltd ADR’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Takeda Pharmaceutical Co Ltd ADR (United States)
Takeda Pharmaceutical Co Ltd ADR is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is Takeda Pharmaceutical Co Ltd ADR?
What is the latest Takeda Pharmaceutical Co Ltd ADR price?
Is Takeda Pharmaceutical Co Ltd ADR in an uptrend?
How volatile is Takeda Pharmaceutical Co Ltd ADR?
What factors affect Takeda Pharmaceutical Co Ltd ADR?
Which trading strategies trade Takeda Pharmaceutical Co Ltd ADR?
How are Takeda Pharmaceutical Co Ltd ADR returns analysed?
Where can I download free Takeda Pharmaceutical Co Ltd ADR historical data?
Free Takeda Pharmaceutical Co Ltd ADR historical data (last 10 years)
Browse or instantly download the last 10 years of Takeda Pharmaceutical Co Ltd ADR daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.TAK.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 21.77 |
| 2026-11-19 | 21.41 |
| 2026-11-18 | 21.27 |
| 2026-11-17 | 21.64 |
| 2026-11-16 | 21.59 |
| 2026-11-13 | 21.43 |
| 2026-11-12 | 21.12 |
| 2026-11-11 | 20.84 |
| 2026-11-10 | 20.93 |
| 2026-11-09 | 21.09 |
About this stock
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.